Although the PD-L1 test plays a potentially significant role in the management of multiple advanced carcinomas, objective standardization for this test has not been achieved; hence, its current use in the clinical practice poses a twofold risk to patients: false positive could result in potentially toxic therapies resulting in unforeseen complications, such as miscarriages, or PD-L1 false negatives would benefit from therapy but are excluded from receiving treatment (Reisenbichler et al., 2020). This evidence concerns the gene CD274 and carcinoma.